Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/IIa, Multicenter, Open-label Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies

NCT05955105 is registered in ClinicalTrials.gov with Innolake Biopharm as lead sponsor.

NCT NCT05955105
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05955105 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/IIa, Multicenter, Open-label Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies
Lead sponsor
Innolake Biopharm
Phase
Phase 1/2
Overall status
Unknown status
Start date
July 25, 2023
Completion date
July 24, 2026
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer, classic hodgkin lymphoma, endometrial cancer, head and neck cancer, melanoma, nasopharyngeal carcinoma, non small cell lung cancer, ovarian cancer, soft tissue sarcoma, triple negative breast cancer